AbbVie is one step closer to challenging Gilead Sciences' dominance in the hepatitis C market, securing a likely European approval for its rival combo treatment as it awaits a U.S. nod.
French startup Enterome Bioscience has been inking deals and raking in funds to develop its personalized microbiome tests. Now, the company is teaming up with AbbVie to create molecular diagnostic tools that will help find the best therapies for patients with Crohn's disease.
The EMA responded quickly to the publication of the letter, issuing a release to outline its approach to the redaction of commercial confidential information.
AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.
AbbVie is heralding positive new data on its hepatitis C cocktail, touting the treatment's benefit in some tough-to-treat patients as it prepares for a head-to-head competition with market leader Gilead Sciences.
In an interview with Investor's Business Daily, Shire CEO Flemming Ornskov hints that he'd like to do something similar to the $4.5 billion ViroPharma acquisition, which added a new product to the portfolio while helping spur sales of an existing drug.
A $1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $55 billion agreement. But investors? At least one may still be planning a little ax-grinding.
Myriad Genetics has struck an expanded deal to use its Tumor BRACAnalysis CDx as a companion diagnostic with AbbVie's veliparib in helping to detect breast cancer.
Express Scripts--which has made its feelings well known when it comes to the high cost of Gilead's next-gen hepatitis C drugs--says it may quickly change its preferred drug formulary to favor a anticipated challenger from the Illinois company, Reuters reports, provided it's clinically equivalent--and less expensive, of course.
No Shire? No problem for AbbVie. At least, for now.